Journal
ADVANCED HEALTHCARE MATERIALS
Volume 7, Issue 3, Pages -Publisher
WILEY
DOI: 10.1002/adhm.201700701
Keywords
circulating tumor cells; poly(3, 4-ethylene-dioxythiophene)s; prostate cancer; responsive materials; RNA biomarkers
Funding
- Ministry of Science and Technology (MOST) of Taiwan [MOST-104-2113-M-001-025-MY2]
- Academia Sinica Research Project on Nano Science and Technology
- Academia Sinica Thematic Project
- DoD [W81XWH-11-1-0422, PC151088]
- Steven Spielberg Discovery Fund in Prostate Cancer Research
- Prostate Cancer Foundation (PCF)
- St. Anthony Prostate Cancer Research Fund
- CD McKinnon Memorial Fund for Neuroendocrine Prostate Cancer
- Berns Family Fund
- PCF
- UCLA Prostate Cancer SPORE Program
- NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program [R21 CA151159, R33 CA157396]
- NIH/NCI Alliance for Nanotechnology in Cancer program [U01 CA 198900]
- NATIONAL CANCER INSTITUTE [R01CA218356, R33CA157396, R21CA151159, U01CA198900, R33CA174562] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A glycan-stimulated and poly(3,4-ethylene-dioxythiophene)s (PEDOT)-based nanomaterial platform is fabricated to purify circulating tumor cells (CTCs) from blood samples of prostate cancer (PCa) patients. This new platform, phenylboronic acid (PBA)-grafted PEDOT NanoVelcro, combines the 3D PEDOT nanosubstrate, which greatly enhances CTC capturing efficiency, with a poly(EDOT-PBA-co-EDOT-EG3) interfacial layer, which not only provides high specificity for CTC capture upon antibody conjugation but also enables competitive binding of sorbitol to gently release the captured cells. CTCs purified by this PEDOT NanoVelcro chip provide well-preserved RNA transcripts for the analysis of the expression level of several PCa-specific RNA biomarkers, which may provide clinical insights into the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
